Patents by Inventor June X. Zou

June X. Zou has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS FOR TREATING CANCER WITH RORGAMMA INHIBITORS
    Publication number: 20210161837
    Abstract: The present invention provides compositions, methods, and kits comprising one or more compounds of Formula I, such as XY018, alone or in combination with one or more anticancer drugs, such as an anti-androgen drug, that are useful for treating cancer, e.g., prostate cancer, such as castration-resistant prostate cancer (CRPC), and numerous other types of cancer including lung cancer, breast cancer, liver cancer, ovarian cancer, endometrial cancer, bladder cancer, colon cancer, gastric cancer, lymphoma, and glioma.
    Type: Application
    Filed: June 30, 2020
    Publication date: June 3, 2021
    Applicants: The Regents of the University of California, Guangzhou Institutes of Biomedicine and Health, U.S. Government represented by the Department of Veterans Affairs
    Inventors: Hongwu Chen, June X. Zou, Junjian Wang, Demin Cai, Yong Xu, Xiaoqian Xue, Yan Zhang
  • Methods for treating cancer with ROR? inhibitors
    Patent number: 10959984
    Abstract: The present invention provides compositions, methods, and kits comprising one or more ROR? inhibitors, alone or in combination with one or more anticancer drugs, such as an anti-androgen drug, that are useful for treating cancer, e.g., prostate cancer, such as castration-resistant prostate cancer (CRPC), and numerous other types of cancer including lung cancer, breast cancer, liver cancer, ovarian cancer, endometrial cancer, bladder cancer, colon cancer, lymphoma, and glioma.
    Type: Grant
    Filed: September 11, 2017
    Date of Patent: March 30, 2021
    Assignee: The Regents of the University of California
    Inventors: Hongwu Chen, June X. Zou, Junjian Wang
  • METHODS FOR TREATING CANCER WITH RORGAMMA INHIBITORS
    Publication number: 20190192454
    Abstract: The present invention provides compositions, methods, and kits comprising one or more compounds of Formula I, such as XY018, alone or in combination with one or more anticancer drugs, such as an anti-androgen drug, that are useful for treating cancer, e.g., prostate cancer, such as castration-resistant prostate cancer (CRPC), and numerous other types of cancer including lung cancer, breast cancer, liver cancer, ovarian cancer, endometrial cancer, bladder cancer, colon cancer, gastric cancer, lymphoma, and glioma.
    Type: Application
    Filed: July 17, 2018
    Publication date: June 27, 2019
    Applicants: The Regents of the University of California, Guangzhou Institutes of Biomedicine and Health, U.S. Government represented by the Department of V eterans Affairs
    Inventors: Hongwu Chen, June X. Zou, Junjian Wang, Demin Cai, Yong Xu, Xiaoqian Xue, Yan Zhang
  • METHODS FOR TREATING CANCER WITH RORGAMMA INHIBITORS
    Publication number: 20180085348
    Abstract: The present invention provides compositions, methods, and kits comprising one or more ROR? inhibitors, alone or in combination with one or more anticancer drugs, such as an anti-androgen drug, that are useful for treating cancer, e.g., prostate cancer, such as castration-resistant prostate cancer (CRPC), and numerous other types of cancer including lung cancer, breast cancer, liver cancer, ovarian cancer, endometrial cancer, bladder cancer, colon cancer, lymphoma, and glioma.
    Type: Application
    Filed: September 11, 2017
    Publication date: March 29, 2018
    Applicant: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Hongwu Chen, June X. Zou, Junjian Wang
  • ANCCA as a Diagnostic Biomarker and Therapeutic Target for Breast Cancers
    Publication number: 20130261167
    Abstract: The present invention provides methods of diagnosing breast cancer, confirming a diagnosis of breast cancer, predicting the survival of a breast cancer patient, and providing a therapeutic target of treatment in a breast cancer patient by measuring relatively increased expression levels of ANCCA. Expression levels of ANCCA can be measured be determining the levels mRNA or protein. The expression levels can be compared to a predetermined threshold level or to a control, e.g., a positive or negative control.
    Type: Application
    Filed: September 23, 2011
    Publication date: October 3, 2013
    Applicant: The Regents Of The University Of California
    Inventors: Hong-Wu Chen, June X. Zou